Cite
HARVARD Citation
Ascierto, P. et al. (2023). Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. Lancet oncology. 24 (1), pp. 33-44. [Online].